eating healthy Rynatuss Tablets most respected

waiting for Rynatuss Tablets generally
 
Photo :Rynatuss Tablets

lots of people Rynatuss Tablets Generic Name: carbetapentane tannate, chlorpheniramine tannate, ephedrine tannate, and phenylephrine tannate Dosage Form: tablet Dosage Professional Interactions Reviews Images More Support Group Q & A Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. Rynatuss Tablets IN-0717-16 Rev. 1/09 Description RYNATUSS Tablets are an antitussive/antihistamine/nasal decongestant/bronchodilator combination. Each tablet contains: Carbetapentane Tannate 60 mg Chlorpheniramine Tannate 5 mg Ephedrine Tannate 10 mg Phenylephrine Tannate 10 mg Other ingredients: corn starch, dibasic calcium phosphate, FD&C Blue No. 1, FD&C Red No. 40, magnesium stearate, methylcellulose, polygalacturonic acid, povidone, talc. Slideshow A Joint Effort: A Provider's Guide To Orthopedic Pain Options Clinical Pharmacology RYNATUSS Tablets combine the antitussive action of carbetapentane, the sympathomimetic decongestant effect of phenylephrine, the antihistaminic action of chlorpheniramine, and the bronchodilator action of ephedrine. Indications and Usage RYNATUSS Tablets are indicated for the symptomatic relief of cough associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis. Appropriate therapy should be provided for the primary disease. Contraindications RYNATUSS Tablets are contraindicated for newborns, nursing mothers, and patients who are sensitive to any of the ingredients or related compounds. Warnings Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, narrow angle glaucoma, or prostatic hypertrophy. Do not use in patients taking monoamine oxidase (MAO) inhibitors, or for 14 days after stopping treatment with an MAOI. This product contains an antihistamine which may cause drowsiness and may have additive central nervous system (CNS) effects with alcohol or other CNS depressants (e.g., hypnotics, sedatives, tranquilizers). Precautions General: Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients. Antihistamines may cause excitation, particularly in children, but their combination with sympathomimetics may cause either mild stimulation or mild sedation. Information for patients: Caution patients against drinking alcoholic beverages or engaging in potentially hazardous activities requiring alertness, such as driving a car or operating machinery, while using this product. Patients should be warned not to use this product if they are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson s disease), or for 2 weeks after stopping the MAOI drug. If patients are uncertain whether a prescription drug contains an MAOI, they should be instructed to consult a health professional before taking such a product. Drug interactions: MAO inhibitors may prolong and intensify the anticholinergic effects of antihistamines and the overall effects of sympathomimetic agents. Carcinogenesis, mutagenesis, impairment of fertility: No long term animal studies have been performed with RYNATUSS Tablets. Pregnancy: Teratogenic effects: Pregnancy Category C. Animal reproduction studies have not been conducted with RYNATUSS Tablets. It is also not known whether RYNATUSS Tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RYNATUSS Tablets should be given to a pregnant woman only if clearly needed. Nursing mothers: RYNATUSS Tablets should not be administered to a nursing woman. Adverse Reactions To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Adverse effects associated with RYNATUSS Tablets at recommended doses have been minimal. The most common have been drowsiness, sedation, dryness of mucous membranes, and gastrointestinal effects. Serious side effects with oral antihistamines or sympathomimetics have been rare. Overdosage Signs and symptoms: May vary from CNS depression to stimulation (restlessness to convulsions). Antihistamine overdosage in young children may lead to convulsions and death. Atropine-like signs and symptoms may be prominent. Treatment: Induce vomiting if it has not occurred spontaneously. Precautions must be taken against aspiration especially in infants, children, and comatose patients. If gastric lavage is indicated, isotonic or half-isotonic saline solution is preferred. Stimulants should not be used. If hypotension is a problem, vasopressor agents may be considered. Dosage and Administration Administer the recommended dose every 12 hours. RYNATUSS Tablets: Adults 1 to 2 tablets. How Supplied RYNATUSS Tablets are mauve, capsule-shaped, scored on one side and imprinted RYNATUSS 717 on the other side, containing in each tablet: carbetapentane tannate 60 mg, chlorpheniramine tannate 5 mg, ephedrine tannate 10 mg, phenylephrine tannate 10 mg, available in bottles of 100 (NDC 0037-0717-92). Storage: Store at controlled room temperature 20 -25 C (68 -77 F). Dispense in a tight container. Protect from moisture. Produced under license from JFC Technologies Bound Brook, NJ, U.S.A. U.S. Patents 5,599,846; 5,663,415 To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . MEDA Pharmaceuticals Meda Pharmaceuticals Inc. Somerset, New Jersey 08873-4120 Printed in U.S.A. Rev. 1/09 Package Label - Principal Display Panel 100 Tablet Bottle NDC 0037-0717-92 100 Tablets RYNATUSS (carbetapentane tannate, chlorpheniramine tannate, ephedrine tannate, phenylephrine tannate) Each tablet contains: Carbetapentane Tannate 60 mg Chlorpheniramine Tannate 5 mg Ephedrine Tannate 10 mg Phenylephrine Tannate 10 mg Rx Only MEDA Pharmaceuticals LB-071701-09 Rev. 2/08 Usual Dosage: See package insert. Store at controlled room temperature 20 -25 C (68 -77 F). Protect from moisture. Dispense in a tight container. Tablet shade may vary among lots; identity and purity of drug are unaffected. Produced under license from JFC Technologies Bound Brook, NJ U.S.A. U.S. Patents 5,599,846; 5,663,415 MEDA Pharmaceuticals Meda Pharmaceuticals Inc. Somerset, New Jersey 08873-4120 RYNATUSS carbetapentane tannate, chlorpheniramine tannate, ephedrine tannate, and phenylephrine tannate tablet Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0037-0717 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CARBETAPENTANE TANNATE (CARBETAPENTANE TANNATE) CARBETAPENTANE TANNATE 60 mg CHLORPHENIRAMINE TANNATE (CHLORPHENIRAMINE TANNATE) CHLORPHENIRAMINE TANNATE 5 mg EPHEDRINE TANNATE (EPHEDRINE TANNATE) EPHEDRINE TANNATE 10 mg PHENYLEPHRINE TANNATE (PHENYLEPHRINE TANNATE) PHENYLEPHRINE TANNATE 10 mg Inactive Ingredients Ingredient Name Strength STARCH, CORN ANHYDROUS DIBASIC CALCIUM PHOSPHATE FD&C BLUE NO. 1 FD&C RED NO. 40 MAGNESIUM STEARATE METHYLCELLULOSE (1500 CPS) POVIDONE TALC POLYGALACTURONIC ACID Product Characteristics Color PINK (MAUVE) Score 2 pieces Shape CAPSULE Size 15mm Flavor Imprint Code RYNATUSS;717 Contains Packaging # Item Code Package Description 1 NDC:0037-0717-92 100 TABLET (TABLET) in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 06/01/1960 01/31/2012 Labeler - Meda Pharmaceuticals Inc. (051229602) Revised: 06/2011 Meda Pharmaceuticals Inc. Next Interactions Print this page Add to My Med List More about Rynatuss (carbetapentane / chlorpheniramine / ephedrine / phenylephrine) Dosage Information Drug Images Drug Interactions Support Group 0 Reviews Add your own review/rating Drug class: upper respiratory combinations} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Availability Discontinued C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug WADA Class Anti-Doping Classification Drug Class Upper respiratory combinations Related Drugs upper respiratory combinations Promethazine DM , Cheratussin AC , Mucinex DM Rynatuss Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Rynatuss Images Rynatuss 60 mg / 5 mg / 10 mg / 10 mg (WALLACE 717 ) View larger images} } be happy


dissipate Rynatuss Tablets out of the blue


EmoticonEmoticon